Clinical trial
A Phase 2, Multi-center, Randomized, Dose-Ranging, Placebo-Controlled, Double-blind Study of the Relaxin Agonist R2R01 in Patients at High Risk for Cardiac Surgery Associated- Acute Kidney Injury
NCT07625553 is registered in ClinicalTrials.gov with River 2 Renal Corp. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Multi-center, Randomized, Dose-Ranging, Placebo-Controlled, Double-blind Study of the Relaxin Agonist R2R01 in Patients at High Risk for Cardiac Surgery Associated- Acute Kidney Injury
- Lead sponsor
- River 2 Renal Corp.
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- April 7, 2026
- Completion date
- April 30, 2027
- Enrollment
- 430 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.